Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TPExtreme trial: what clinicians have said so far
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
- NCT02268695 ↗
- Completed
- Groupe Oncologie Radiotherapie Tete et Cou
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TPExtreme yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TPExtreme so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Cisplatin; 5-Fluorouracile; Docetaxel; Cetuximab; granulocyte colony-stimulating factor (G-CSF)
- Arms
- EXTREME: Cisplatin, 5-FU and Cetuximab · Active comparator
- TPEx: Cisplatin, Docetaxel and Cetuximab · Experimental
- Enrollment
- 541
- Primary outcomes
- Overall survival
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou with Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, AIO-Studien-gGmbH
- Start
- Oct 10, 2014
- Primary completion
- Dec 31, 2021
- Results posted
- No
- Registry record
- NCT02268695 · updated Aug 23, 2022
Publications
linked from the registry- Fraslin AM, Auperin A, Even C, Fayette J, Saada-Bouzid E, Lafond C, Geoffrois L; TPExtreme-ECO Group; Bourhis J, Guigay J, Bonastre J. Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Value Health. 2025 Dec;28(12):1793-1801. doi: 10.1016/j.jval.2025.07.032. Epub 2025 Aug 21. PubMed 40848743
- Atsou K, Auperin A, Guigay J, Salas S, Benzekry S. Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma. CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):540-550. doi: 10.1002/psp4.13294. Epub 2024 Dec 25. PubMed 39722558
- Guigay J, Auperin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clement C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. PubMed 33684370